Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043851 | 1.00 | GLO1 (0.72) | GLO1ALDH1A1KMT2ALMNAKDM4E | |
| SCHEMBL16474351 | 0.89 | GLO1 (0.67) | GLO1ALDH1A1KMT2ALMNAKDM4E | |
| SCHEMBL1095181 | 0.88 | GLO1 (0.73) | GLO1ALDH1A1KMT2ALMNAKDM4E | |
| SCHEMBL14267786 | 0.88 | GLO1 (0.59) | GLO1ALDH1A1KMT2ALMNAKDM4E | |
| SCHEMBL1095182 | 0.88 | GLO1 (0.73) | GLO1ALDH1A1KMT2ALMNAKDM4E | |
| SCHEMBL8018753 | 0.88 | GLO1 (0.90) | GLO1ALDH1A1KMT2ALMNAKDM4E | |
| SCHEMBL11681247 | 0.86 | GLO1 (0.82) | GLO1ALDH1A1KMT2ALMNAKDM4E | |
| SCHEMBL11097676 | 0.86 | GLO1 (0.77) | GLO1ALDH1A1KMT2ALMNAKDM4E | |
| SCHEMBL11097674 | 0.86 | GLO1 (0.77) | GLO1ALDH1A1KMT2ALMNAKDM4E | |
| SCHEMBL30172648 | 0.85 | GLO1 (0.72) | GLO1ALDH1A1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2018-07-10 | — | — | US | disclosed |
| US-20170312239-A1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2017-11-02 | — | — | US | disclosed |
| US-9561202-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2017-02-07 | — | — | US | disclosed |
| US-9345680-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2016-05-24 | — | — | US | disclosed |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150265563-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-9133099-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2015-09-15 | — | — | US | disclosed |
| US-20150045436-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2015-02-12 | — | — | US | disclosed |
| US-8710100-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2014-04-29 | — | — | US | disclosed |
| EP-1910270-B1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | NOGRA PHARMA LTD (IE) | 2013-05-08 | — | — | EP | disclosed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED | 2009-12-03 | — | — | US | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| EP-1910270-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | disclosed |
| US-7326732-B2 | EP2 receptor agonists | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| WO-2007010516-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
| EP-1723132-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | ASTERAND, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005080367-A1 | EP2 RECEPTOR AGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312239-A1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | EGFR, ERBB3, FGFR3 | GLO1 4009/4885ALDH1A1 2799/4885KMT2A 4180/4885 |
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | GLO1 4009/4885ALDH1A1 2799/4885KMT2A 4180/4885 |
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | PTGER2, PTGER1, TBXA2R | GLO1 4620/4885ALDH1A1 2212/4885KMT2A 2036/4885 |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | GLO1 4009/4885ALDH1A1 2799/4885KMT2A 4180/4885 |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PTGER3, PTGER4, PTGES3 | GLO1 3155/4885ALDH1A1 1302/4885KMT2A 4712/4885 |
| US-20150265563-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | GLO1 4009/4885ALDH1A1 2799/4885KMT2A 4180/4885 |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | PTGER3, PTGER1, PTGER4 | GLO1 3288/4885ALDH1A1 1588/4885KMT2A 4755/4885 |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | EGFR, ERBB3, FGFR3 | GLO1 4009/4885ALDH1A1 2799/4885KMT2A 4180/4885 |
| US-20150045436-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | GLO1 4010/4885ALDH1A1 2878/4885KMT2A 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.